Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Provided By GlobeNewswire
Last update: Sep 19, 2023
PHILADELPHIA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September:
